8th Annual Wiffle For Cancer Set for June 10 
Patch.com
Tournament held in memory of Ridgewood's Nick Curry, who died of Ewing sarcoma before he was set to begin his freshman year at Colby College. Nick Currey passed away seven years ago; his family has held the annual Wiffle for Cancer game each passing ...

 

Pazopanib in Sarcoma: Clinically Significant Benefit? 
Medscape
May 16, 2012 ? The clinical trial showing benefit from pazopanib (Votrient) in soft tissue sarcoma, which was the basis for the drug's recent approval for this indication, was published online today in the Lancet. The trial, known as PALLETE ...
Pazopanib Works as Sarcoma Salvage Tx MedPage Today
Pazopanib Active in Metastatic Soft-Tissue Sarcoma Doctors Lounge
'Advanced Soft Tissue Sarcoma, Pazopanib Improves Progression-Free Survival' Medical News Today

all 4 news articles » 

1 Million 4 Anna Foundation Launches in Memory of Anna Basso 
EON: Enhanced Online News (press release)
DALLAS--(EON: Enhanced Online News)--The 1 Million 4 Anna Foundation, an organization founded in memory of Anna Lee Basso, officially launched today and aims to win the fight against Ewing's Sarcoma today, tomorrow, and until it's gone.

and more » 

Glaxo's Votrient Gains US Approval for Deadly Sarcomas 
BusinessWeek
By Anna Edney on April 26, 2012 GlaxoSmithKline Plc (GSK) won US clearance to expand marketing of its 2-year-old kidney-cancer pill Votrient for rare malignancies known as soft-tissue sarcomas. The Food and Drug Administration approved the drug for ...
FDA Approves Pazopanib for Advanced Soft Tissue Sarcoma Medscape
FDA approves Votrient® for treatment of patients with certain types of ... MarketWatch (press release)
PRESS RELEASE: FDA approves Votrient for advanced soft tissue sarcoma Fox Business
U.S. News & World Report  -NASDAQ 
all 63 news articles » 

Kidney Drug Works for Other Cancers 
dailyRx
A team of researchers from the Netherlands working with the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group found that the drug, Votrient (pazopanib) was effective in stopping growth for a short amount of ...

 

PRESS RELEASE: FDA approves Votrient for advanced soft tissue sarcoma 
Wall Street Journal
The US Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, ...
SFA Applauds the FDA's Approval of Votrient MarketWatch (press release)
WSJ BLOG/Health: FDA OKs New Treatment for Soft-Tissue Sarcoma Patients Fox Business
FDA approves Votrient® for treatment of patients with certain types of ... PR Newswire (press release)
Cancer Network  -Reuters  -Oncology Nurse Advisor 
all 26 news articles » 

Pazopanib: First Drug for Sarcoma in Decades 
Medscape
May 3, 2012 ? Pazopanib (Votrient), approved last week in the United States for the treatment of advanced soft tissue sarcomas, is the first new drug option for these patients in decades. Pazopanib, which targets VEGF, PDGF, and several tyrosine ...

 

Genome-wide recruitment to Polycomb-modified chromatin and activity regulation ... 
7thSpace Interactive (press release)
SYT-SSX is the oncogene associated with synovial sarcoma (SS), a stem cell disease. SYT-SSX is thought to be responsible for sarcoma initiation and development. It interacts with components of Polycomb and SWI/SNF complexes, the two epigenetic ...

 

Research Identifies Important Proteins that Play Role in Sarcoma Cancer Growth 
eMaxHealth
By Denise Reynolds RD on May 15, 2012 - 9:52am for eMaxHealth Sarcomas are rare forms of cancer which arise from bone, fat, muscle or vascular tissues. Currently there are no approved drugs for treatment of sarcoma in the United States, although one ...

 

Targeted therapy with pazopanib prolongs progression-free survival in advanced ... 
Medical Xpress
For patients with metastatic soft-tissue sarcoma whose disease has progressed following standard chemotherapy, treatment with pazopanib (a drug that targets the growth of new cancer-related blood vessels) nearly tripled progression-free survival (PFS) ...

and more »